

Genomic and Personalized Medicine

Second Edition

Edited by

Geoffrey S. Ginsburg & Huntington F. Willard



VOLUME

2



Genomic and Personalized Medicine

Volume 2 Second Edition

Edited by

Geoffrey S. Ginsburg, M.D., Ph.D.

Director, Genomic Medicine

Duke Institute for Genome Sciences & Policy

Executive Director, Center for Personalized Medicine

Duke University Health System

Professor of Medicine

Duke University School of Medicine

Durham, North Carolina 27710

and

Huntington F. Willard Ph.D.


Institute Director

Duke Institute for Genome Sciences & Policy

Nanaline H. Duke Professor of Genome Sciences

Duke University

Durham, North Carolina 27708



AMSTERDAM • BOSTON • HEIDELBERG • LONDON • NEW YORK • OXFORD
PARIS • SAN DIEGO • SAN FRANCISCO • SYDNEY • TOKYO
Academic Press is an imprint of Elsevier



Academic Press is an imprint of Elsevier
32 Jamestown Road, London NW1 7BY, UK
225 Wyman Street, Waltham, MA 02451, USA
525 B Street, Suite 1800, San Diego, CA 92101-4495, USA

First edition 2009
Second edition 2013

Copyright © 2013 Elsevier Inc. All rights reserved
with the exception of the Chapters 26, 28, 37, 68, 94, 101 which are in the public domain

No part of this publication may be reproduced, stored in a retrieval system or transmitted
in any form or by any means electronic, mechanical, photocopying, recording or
otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights
Department in Oxford, UK: phone (+ 44) (0) 1865 843830; fax (+44) (0) 1865 853333;
email: permissions@elsevier.com. Alternatively, visit the Science and Technology Books
website at www.elsevierdirect.com/rights for further information

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons
or property as a matter of products liability, negligence or otherwise, or from any use
or operation of any methods, products, instructions or ideas contained in the material
herein. Because of rapid advances in the medical sciences, in particular, independent
verification of diagnoses and drug dosages should be made

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library

Library of Congress Cataloging-in-Publication Data

A catalog record for this book is available from the Library of Congress

ISBN : 978-0-12-382227-7 (set)
ISBN : 978-0-12-415938-9 (vol. 1)
ISBN : 978-0-12-415937-2 (vol. 2)

For information on all Academic Press publications
visit our website at www.elsevierdirect.com

Typeset by MPS Limited, Chennai, India
www.adi-mps.com

Printed and bound in United States of America

12 13 14 15 10 9 8 7 6 5 4 3 2 1

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER BOOK AID International Sabre Foundation

Genomic and Personalized Medicine

Second Edition

Table of Contents

VOLUME 2

PART III DISEASE-BASED GENOMIC AND PERSONALIZED MEDICINE: GENOME DISCOVERIES AND CLINICAL SIGNIFICANCE

Section 5 Cardiovascular Genomic Medicine 487

- 44 Hypertension 488
Patricia B. Munroe and Toby Johnson
- 45 Lipoprotein Disorders 501
Sekar Kathiresan and Daniel J. Rader
- 46 Coronary Artery Disease and Myocardial Infarction 516
Samir B. Damani and Eric J. Topol
- 47 Atherosclerosis, Vulnerable Plaques, and Acute Coronary Syndromes 530
Jacob Fog Bentzon and Erling Falk
- 48 Heart Failure 540
Ivor J. Benjamin
- 49 Cardiac Transplant Rejection 557
Michael X. Pham and James Yee
- 50 Hypertrophic Cardiomyopathies 572
J. Martijn Bos, Steve R. Ommen, and Michael J. Ackerman
- 51 Arrhythmias 587
Barry London
- 52 Hemostasis and Thrombosis 602
Richard C. Becker, Deepak Voora, and Svati H. Shah
- 53 Peripheral Arterial Disease 612
Arabindra B. Katwal, Ayotunde O. Dokun, and Brian H. Annex
- 54 Congenital Heart Disease 624
Lisa J. Martin and D. Woodrow Benson
- 55 Perioperative Genomics 635
Mihai V. Podgoreanu
- 56 Stroke 655
Matthew B. Lanktree, Tisha R. Joy, and Robert A. Hegele

Section 6 Oncology Genomic Medicine 667

- 57 Lymphomas 668
Sandeep Dave and Katherine Walsh
- 58 Leukemias 675
Lars Bullinger and Stefan Fröhling
- 59 Lung Cancer 691
Hector Marquez, Praveen Govender, Jerome S. Brody, and Hasmeena Kathuria
- 60 Breast Cancer 707
Philip S. Bernard
- 61 Ovarian Cancer 714
Tanja Pejovic, Matthew L. Anderson, and Kunle Odunsi
- 62 Colorectal Cancer 722
Ad Geurts van Kessel, Ramprasath Venkatachalam, and Roland P. Kuiper
- 63 Prostate Cancer 733
Aubrey R. Turner, Junjie Feng, Wennuan Liu, Jin Woo Kim, and Jianfeng Xu
- 64 Head and Neck Cancer 742
Giovana R. Thomas and Gina Jefferson
- 65 Brain Tumors and Gliomas 749
Sean E. Lawler and E. Antonio Chiocca
- 66 Melanoma 765
Christina K. Augustine, Jennifer A. Freedman, Georgia M. Beasley, and Douglas S. Tyler
- 67 Metastatic Cancer 776
Jude Alsarraj and Kent W. Hunter
- 68 Bioinformatics in Personalized Cancer Care 789
Kenneth H. Buetow
- 69 Diagnostic-therapeutic Combinations 798
Jeffrey S. Ross

Section 7 Inflammatory and Metabolic Disease Genomic Medicine 821

- 70 Autoimmune Disorders 822
Sergio E. Baranzini

71	Rheumatoid Arthritis <i>Robert M. Plenge</i>	839	88	Schizophrenia and Bipolar Disorder <i>Hywel J. Williams, Michael C. O'Donovan, Nicholas Craddock, and Michael J. Owen</i>	1051
72	Multiple Sclerosis <i>Francisco J. Quintana and Howard L. Weiner</i>	853	89	Depression <i>Brigitta Bondy</i>	1059
73	Inflammatory Bowel Disease <i>Eleanora Anna Margaretha Festen, Cisca Wijmenga, and Rinse K. Weersma</i>	863	90	Autism Spectrum Disorders <i>Timothy W. Yu, Michael Coulter, Maria Chahrour, and Christopher A. Walsh</i>	1067
74	Asthma <i>Scott T. Weiss</i>	879	91	Eye Diseases <i>Janey L. Wiggs</i>	1075
75	Chronic Obstructive Pulmonary Disease <i>Peter J. Barnes</i>	887	92	Glaucoma <i>Yutao Liu and R. Rand Allingham</i>	1082
76	Interstitial Lung Disease <i>Mark P. Steele, Eric B. Meltzer, and Paul W. Noble</i>	899	Section 9 Infectious Disease Genomic Medicine		1095
77	Peptic Ulcer Disease <i>John Holton</i>	914	93	Diagnosis and Classification of Pathogens <i>Octavio Ramilo and Asunción Mejías</i>	1096
78	Cirrhosis <i>Nicholas A. Shackel, Keyur Patel, and John McHutchison</i>	935	94	Host–Pathogen Interactions <i>Scott D. Kobayashi and Frank R. DeLeo</i>	1106
79	Systemic Sclerosis <i>Sevdalina Lambova and Ulf Müller-Ladner</i>	955	95	Microbial Vaccine Development <i>M. Anthony Moody</i>	1119
80	Systemic Lupus Erythematosus <i>Benjamin Rhodes and Timothy J. Vyse</i>	970	96	Bacterial Infections <i>Yurong Zhang, Sun Hee Ahn, and Vance G. Fowler, Jr</i>	1129
81	Osteoarthritis <i>Virginia Byers Kraus</i>	983	97	Emerging Viral Infections <i>Albert D.M.E. Osterhaus and Saskia L. Smits</i>	1142
82	Diabetes <i>Jose C. Florez</i>	990	98	Sepsis <i>Stephen F. Kingsmore, Christopher W. Woods, and Carol J. Saunders</i>	1155
83	The Metabolic Syndrome <i>Matthew B. Lanktree, Tisha R. Joy, and Robert A. Hegele</i>	1006	99	Viral Hepatitis <i>Nicholas A. Shackel, Keyur Patel, and John McHutchison</i>	1173
Section 8 Neuropsychiatric Disease Genomic Medicine		1017	100	Malaria <i>Nadia Ponts and Karine G. Le Roch</i>	1191
84	Neuroscience and the Genomic Revolution: An Overview <i>Neelroop N. Parikshak and Daniel H. Geschwind</i>	1018	101	HIV Pharmacogenetics and Pharmacogenomics <i>C. William Wester, Sophie Limou, and Cheryl A. Winkler</i>	1211
85	Alzheimer's Disease <i>Lars Bertram</i>	1028	Glossary		1231
86	Parkinson's Disease <i>Jing Zhang and Tessandra Stewart</i>	1034	Index		1251
87	Epilepsy <i>Sanjay M. Sisodiya</i>	1044			

VOLUME 1

Foreword	ix
Preface	xi
Acknowledgments	xiii
Abbreviations	xv
Contributors	xxix

PART I GENOME-BASED APPROACHES TO BIOLOGY AND MEDICINE

Section 1 Principles of Human Genomics 3

- 1 The Human Genome: A Window on Human Genetics, Biology, and Medicine 4
Huntington F. Willard
- 2 Mapping the Functional Genome: The ENCODE and Roadmap Epigenomics Projects 28
Sam John, Hao Wang, and John A. Stamatoyannopoulos
- 3 Population Perspectives on Genome Variation and Complex Disease 41
Steven A. McCarroll
- 4 Gene–Environment Interactions: Eco-Genetics and Toxicogenomics 50
Gilbert S. Omenn
- 5 Systems Biology and Systems Medicine 60
Nathan D. Price, Lucas B. Edelman, Inyoul Lee, Hyuntae Yoo, Daehee Hwang, George Carlson, David J. Galas, James R. Heath, and Leroy Hood

Section 2 Genome-based Approaches for Genomic and Personalized Medicine 73

- 6 Personal Genomics 74
Joanna L. Mountain
- 7 Whole-Genome Sequencing: New Technologies, Approaches, and Applications 87
Elaine R. Mardis
- 8 Human Genome Variation Discovery via Exome and Whole-Genome Sequencing 94
Samuel Levy
- 9 Clinical Genome Sequencing 102
Robert C. Green, Heidi L. Rehm, and Isaac S. Kohane

- 10 Structural Genomic Variation in the Human Genome 123
Charles Lee
- 11 Clinical Applications of Whole-Genome Chromosomal Microarray Analysis 133
David H. Ledbetter, Erin Rooney Riggs, and Christa Lese Martin
- 12 Transcriptomics in the Age of Ultra High-Throughput Sequencing 145
Ryan D. Morin and Marco Marra
- 13 Quantitative Proteomics in Genomic Medicine 155
M. Arthur Moseley, III
- 14 The Human Microbiome and Personalized Medicine 166
Jun Wang
- 15 Glycomics, Glycobiology, and Glyco-Medicine 173
Hudson H. Freeze and Bobby G. Ng
- 16 Genome-Wide RNA Interference Screening 192
Megan L. Goodall and Jeffrey P. MacKeigan

PART II TRANSLATIONAL APPROACHES IN GENOMIC AND PERSONALIZED MEDICINE


Section 3 Enabling Genomic Strategies, Clinical Research, and Informatics Platforms for Genomic and Personalized Medicine 203

- 17 Application of Human Genome Information to Clinical Practice 204
Geoffrey S. Ginsburg
- 18 Genomic, Personalized Medicine and Public Health 216
Marta Gwinn and Muin J. Khoury
- 19 Biospecimen Banking in the Post-Genome Era 229
Carolyn Compton and Andrea Kelly
- 20 Designing Genomics-Based Clinical Studies 237
Richard Simon
- 21 Genomic Biomarkers in Human Population Studies 247
Jacqueline S. Danik, Nina P. Paynter, and Paul M. Ridker
- 22 Validation of Candidate Protein Biomarkers 263
Maria P. Pavlou and Eleftherios P. Diamandis

23	Translational Bioinformatics for Genomic Medicine <i>Atul J. Butte and David Chen</i>	272	Section 4 Policy Challenges in Genomic and Personalized Medicine	391
24	Electronic Health Records in Genomic Medicine <i>Glenn S. Gerhard, David J. Carey, and Glenn D. Steele, Jr</i>	287	34 Overview of Policy, Ethical and Social Considerations in Genomic and Personalized Medicine <i>Susanne B. Haga</i>	392
25	Clinical Implementation of Genomic Medicine in Primary Care <i>Alex H. Cho and Lori A. Orlando</i>	295	35 Informed Consent <i>Laura M. Beskow</i>	405
26	Family History and Health Risk Assessment <i>Wendy S. Rubinstein</i>	306	36 Educational Issues and Strategies for Genomic Medicine <i>Neil E. Lamb and Chris Gunter</i>	415
27	Clinical Decision Support <i>Kensaku Kawamoto</i>	324	37 Regulatory Issues for Genomic Technologies <i>Janet Woodcock</i>	422
28	Knowledge Management to Support Personalized Healthcare <i>Gregory J. Downing</i>	332	38 Challenges and Regulation of Direct to Consumer Testing <i>Gail Javitt and Joan Scott</i>	433
29	Delivery of Personalized Medicine in an Integrated Healthcare System <i>Marc S. Williams</i>	340	39 Economic Issues and Genomic Medicine <i>David L. Veenstra</i>	440
30	Pharmacogenomics in Drug Discovery and Development <i>Keith J. Johnson and Stephen L. Eck</i>	353	40 Strategic Issues in the Adoption of Genome-Based Diagnostics <i>Myla Lai-Goldman and Hawazin Faruki</i>	447
31	Pharmacogenetics and Pharmacogenomics <i>Howard L. McLeod</i>	362	41 Reimbursement <i>Bruce Quinn, Robert B. Giffin, and Sean R. Tunis</i>	457
32	Point-of-Care Devices <i>Minhaz Uddin Ahmed, April S. Brown, and Pae C. Wu</i>	372	42 Genomics and Patents: A Practical Guide for Genome Scientists and Clinical Researchers <i>Robert Cook-Deegan</i>	464
33	Patient-Specific Pluripotent Stem Cells <i>Gabriella L. Boulting and Kevin C. Eggan</i>	381	43 Public–Private Partnerships in Biomarker Research <i>David N. Wholley</i>	474

Cardiovascular Genomic Medicine

Section 5



44. Hypertension
45. Lipoprotein Disorders
46. Coronary Artery Disease and Myocardial Infarction
47. Atherosclerosis, Vulnerable Plaques, and Acute Coronary Syndromes
48. Heart Failure
49. Cardiac Transplant Rejection
50. Hypertrophic Cardiomyopathy
51. Arrhythmias
52. Hemostasis and Thrombosis
53. Peripheral Arterial Disease
54. Congenital Heart Disease
55. Perioperative Genomics
56. Stroke

CHAPTER



Hypertension

Patricia B. Munroe and Toby Johnson

INTRODUCTION

Elevated blood pressure (BP) or hypertension [≥ 140 mmHg systolic blood pressure (SBP) and/or ≥ 90 mmHg diastolic blood pressure (DBP)] is highly prevalent, affecting 26.4% of people aged 20 or older worldwide (Kearney et al., 2005), and is the leading global cause of preventable death. The World Health Organization (WHO) estimated that in 2004 hypertension accounted for 13% of deaths worldwide; 16.8% in high-income countries and 7.5% in low-income countries, due mainly to coronary heart disease (CHD) and stroke (WHO, 2009). Other complications associated with hypertension include heart failure, peripheral vascular disease, renal impairment, retinal hemorrhage, and visual impairment (WHO, 2002). Prospective observational studies show that the risk of cardiovascular disease (CVD) increases in a roughly linear fashion across the normal population range of BP (Chobanian et al., 2003), and that in older age groups, the risk of cardiovascular disease doubles for each increment of 20 mmHg SBP and 10 mmHg DBP, starting as low as 115 mmHg SBP and 75 mmHg DBP.

Existing anti-hypertensive treatments are effective at the population level, reducing the risk of developing CHD events (fatal and nonfatal) by 25% and the risk of stroke by 33%, per 10 mmHg reduction in SBP and 5 mmHg reduction in DBP achieved, independent of pre-treatment BP level (Law et al., 2009). However, at the individual level, BP is often poorly controlled, and many patients do not achieve < 140 mmHg SBP and < 90 mmHg DBP targets. In the 2006 Health Survey for England, only 28% of patients achieved this target, even

though most were prescribed two or more anti-hypertensive drugs (Falaschetti et al., 2009). For many years, the first-choice therapies were beta-blockers and thiazide diuretics, which were developed more than 50 years ago (Borhani, 1959; Prichard, 1966). More recently angiotensin-converting enzyme inhibitors (ACEi), calcium channel blockers (CCBs), and angiotensin II receptor antagonists (ARBs) have become increasingly preferred, and current guidelines in the United Kingdom recommend ACEi or ARBs as first-line treatment for individuals < 55 years, and CCBs prescribed for individuals > 55 years and those of African or Caribbean ancestry (National Institute for Health and Clinical Excellence, 2011). The ACEi, ARBs, and thiazide diuretics all target the renin-angiotensin-aldosterone system (RAAS), which is a hormonal pathway that maintains normal BP and blood volume (Nguyen Dinh Cat and Touyz, 2011). There are very few new drugs in development for lowering BP in the general population, and only one new therapy has been granted regulatory approval in the past three years. Aliskirin is a first-in-class oral renin inhibitor that also targets the RAAS, and clinical trial data indicate effects on BP comparable to ACEi and ARBs (Musini et al., 2008).

The main causes of hypertension are well known. Lifestyle and genetic effects are both influential. The most important lifestyle risk factors are excess dietary sodium intake, body weight, alcohol consumption, stress, and lack of exercise (Chiong, 2008). Evidence for a genetic component comes from studies of families and twins, and suggests that the heritability (the fraction of BP variance contributed by genetic factors) for both SBP and DBP is between 30% and 50% (Havlik et al.,

1979). However, heritability studies do not identify which genetic differences are important or by what mechanisms they exert their effects on BP. Recent advances in human genetics offer the opportunity to discover hitherto-unknown mechanisms and pathways affecting BP, which could, in principle, be targeted by novel therapeutic approaches and thus improve treatment of hypertension and prevention of CVD.

FINDING BLOOD PRESSURE GENES

Identification of the genetic basis of BP has been a longstanding and challenging research objective (Wallace et al., 2007). Mutations in specific genes causing rare, monogenic forms of hypertension have been successfully identified using linkage analysis and positional cloning. These mutations are in genes primarily expressed in the kidney, and affect salt/water homeostasis (Lifton et al., 2001). Although linkage analysis has had some success in mapping genes for other complex diseases, including type 1 diabetes and Crohn's disease (Brant and Shugart, 2004; Concannon et al., 2005), the use of linkage-based methods has not been successful for finding genes causing essential hypertension (high BP with no obvious medical cause), despite studies of sibling pairs and families with large sample sizes, and up to 400 microsatellite markers across the genome being analyzed (Caulfield et al., 2003; Cowley, 2006; Wu et al., 2006). Alongside genome-wide linkage studies, numerous candidate gene association studies for hypertension have also been carried out, albeit mostly with relatively small sample sizes, and with a general lack of consistency of the replicability of findings (Dominiczak et al., 2004).

However, over the past three years there has been substantial progress, and this success is largely attributable to the advent and rapid technological advances of genome-wide association studies (GWAS) (Hirschhorn and Daly, 2005). Modern GWAS use mass-produced DNA microarrays to genotype 300,000 or more single nucleotide polymorphisms (SNPs), distributed across the whole genome, in each individual. SNPs not directly genotyped can be imputed using correlation structures between multiple SNPs observed in reference panels densely genotyped by the HapMap (International HapMap Consortium, 2003) or 1000G studies (1000 Genomes Project Consortium, 2010). Typically a discovery analysis is conducted, in which hundreds or thousands of individuals are genotyped, and at each SNP (genotyped or imputed) the allele present is tested for association with hypertensive status and/or continuous BP phenotypes. The "BP phenotype" commonly used for GWAS studies is an untreated BP value, or an imputed BP value if the individual is taking anti-hypertensive medication (Tobin et al., 2005). Gender, age, age², and body mass index (BMI) are then included as covariates in an analysis, and a correction for population stratification is included if necessary. Associations that are suggestive or significant after multiple testing correction (genome-wide significant) are typically followed up by genotyping in further independent samples of

individuals to establish definitive genome-wide significance (McCarthy et al., 2008). Most GWAS have used unrelated individuals, for which tests of association require straightforward contingency table or linear regression analyses, although it is also possible to apply GWAS methodology in samples of related individuals (Scuteri et al., 2007).

The Wellcome Trust Case Control Consortium (WTCCC) published the first GWAS results for hypertension in 2007 (Wellcome Trust Case Control Consortium, 2007). This study tested for association by comparing 2000 unrelated hypertensive cases, versus 3000 "common controls." The WTCCC study design used the same "common controls" for seven different disease comparisons, which had a potentially important disadvantage because the controls were from general population samples and therefore were not all non-hypertensive. The WTCCC did not find any genome-wide significant SNPs for hypertension, suggesting common genetic variants affecting risk for hypertension were likely to have relatively small effect sizes and/or were not covered by the Affymetrix 500K genotyping arrays used.

A number of subsequent GWAS tested association with either hypertension or with SBP and DBP as continuous outcomes, and reported a significant association for SBP at SNPs on chromosome 2q24.3, in the *STK39* (serine threonine kinase 39) gene (Wang et al., 2009), a significant association for DBP and hypertension at a SNP on chromosome 16q23.3, upstream of the *CDH13* (adhesion glycoprotein T-cadherin) gene (Org et al., 2009), and a significant association for SBP and DBP at a SNP near the *ATP2B1* (ATPase calcium transporting, plasma membrane 1) gene (ATP=adenosine triphosphate), reported by the Korean Association Resource (KARE) project (Cho et al., 2009). Only variants near *ATP2B1* have been replicated in subsequent studies with much larger sample sizes, suggesting that the associations near *STK39* and near *CDH13* are either false positives or are population-specific effects.

At the same time, Newton-Cheh and colleagues reported results from a candidate gene association study for two BP biomarkers, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), which are peptides with known vasodilatory properties. They tested SNPs near the atrial natriuretic peptide precursor (*NPPA*) and brain natriuretic peptide precursor (*NPPB*) genes, and for two SNPs they found significant association with increased plasma ANP and BNP levels, and, at the same two SNPs, association with decreased SBP and DBP (Newton-Cheh et al., 2009b). This study highlights a more general idea that studying intermediate quantitative phenotypes may increase power to detect associations for the disease phenotype(s) that are ultimately of interest (Plomin et al., 2009).

The modest findings of individual GWAS for BP traits meant that a natural next step was to meta-analyze results from multiple GWAS, and thus achieve effectively much larger sample sizes. The greater power of such studies has led to the identification of 40 distinct loci, each harboring one or more genetic variants with robust and validated association with BP traits (Table 44.1).

TABLE 44.1 Summary of genetic variants robustly associated with blood pressure from peer-reviewed publications

SNP	Locus nickname	Chr	Base pair position (NCBI build 36)	MAF	Discovery cohort ethnicity	Reference
GWAS of SBP and DBP						
*rs17249754	ATP2B1	12	88,584,717	0.37	East Asian	Cho et al., 2009
Intermediate phenotype analysis						
*rs5068	NPPA/NPPB	1	11,828,511	0.06	European	Newton-Cheh et al., 2009b
Meta-analyses of GWAS of SBP, DBP, and hypertension						
<i>Global BPgen Consortium</i>						
rs17367504	MTHFR-NPPB	1	11,785,365	0.14	European	Newton-Cheh et al., 2009a
*rs11191548	CYP17A1-NT5C2	10	104,836,168	0.09	European	
*rs16998073	FGF5	4	81,541,520	0.21	European	
*rs1530440	c10orf107	10	63,194,597	0.19	European	
*rs653178	SH2B3	12	110,470,476	0.47	European	
*rs1378942	CYP1A1-CSK	15	72,864,420	0.35	European	
*rs16948048	ZNF652	17	44,795,465	0.39	European	
<i>CHARGE Consortium</i>						
rs1004467	CYP17A1	10	104,584,497	0.10	European	Levy et al., 2009
*rs381815	PLEKHA7	11	16,858,844	0.26	European	
rs2681492	ATP2B1	12	88,537,220	0.20	European	
rs3184504	SH2B3	12	110,368,991	0.47	European	
*rs9815354	ULK4	3	41,887,655	0.17	European	
*rs11014166	CACNB2	10	18,748,804	0.34	European	
*rs2384550	TBX3-TBX5	12	113,837,114	0.35	European	
rs6495122	CSK-ULK3	15	72,912,698	0.42	European	
*rs880315	CASZ1	1	10,719,453	0.36	East Asian	Takeuchi et al., 2010
<i>AGEN-BP study</i>						
rs17030613	ST7L-CAPZA1	1	112,971,190	0.47	East Asian	Kato et al., 2011
*rs16849225	FIGN-GRB14	2	164,615,066	0.40	East Asian	
*rs6825911	ENPEP	4	111,601,087	0.48	East Asian	
*rs1173766	NPR3	5	32,840,285	0.38	East Asian	
*rs11066280	RPL6-ALDH2	12	111,302,166	0.22	East Asian	
rs35444	TBX3	12	114,036,820	0.25	East Asian	

(continued)

TABLE 44.1 (Continued)

SNP	Locus nickname	Chr	Base pair position (NCBI build 36)	MAF	Discovery cohort ethnicity	Reference
<i>ICBP-GWAS for SBP and DBP</i>						
*rs2932538	MOV10	1	113,018,066	0.25	European	Ehret et al., 2011
*rs13082711	SLC4A7	3	27,512,913	0.22	European	
*rs419076	MECOM	3	170,583,580	0.47	European	
*rs13107325	SLC39A8	4	103,407,732	0.05	European	
*rs13139571	GUCY1A3-GUCY1B3	4	156,864,963	0.24	European	
rs1173771	NPR3-C5orf23	5	32,840,285	0.40	European	
*rs11953630	EBF1	5	157,777,980	0.37	European	
*rs1799945	HFE	6	26,199,158	0.14	European	
*rs805303	BAT2-BAT5	6	31,724,345	0.41	European	
rs1813353	CACNB2(3')	10	18,747,454	0.45	European	
*rs932764	PLCE1	10	95,885,930	0.44	European	
*rs7129220	ADM	11	10,307,114	0.19	European	
*rs633185	FLJ32810-TMEM133	11	100,098,748	0.28	European	
*rs2521501	FES-FURIN	15	89,238,392	0.31	European	
*rs17608766	GOSR2	17	42,368,270	0.14	European	
*rs1327235	JAG1	20	10,917,030	0.46	European	
*rs6015450	GNAS-EDN3	20	57,184,512	0.12	European	
rs17367504	MTHFR-NPPB	1	11,785,365	0.15	European	
rs3774372	ULK4	3	41,852,418	0.17	European	
rs1458038	FGF5	4	81,383,747	0.29	European	
rs4373814	CACNB2 (5')	10	18,459,978	0.45	European	
rs4590817	C10orf107	10	63,137,559	0.16	European	
rs11191548	CYP17A1-NT5C2	10	104,836,168	0.09	European	
rs381815	PLEKHA7	11	16,858,844	0.26	European	
Rs17249754	ATP2B1	12	88,584,717	0.16	European	
rs3184504	SH2B3	12	110,368,991	0.47	European	
rs10850411	TBX5-TBX3	12	113,872,179	0.30	European	
rs1378942	CYP1A1-ULK3	15	72,864,420	0.35	European	
rs12940887	ZNF652	17	44,757,806	0.38	European	

(continued)

TABLE 44.1 (Continued)

SNP	Locus nickname	Chr	Base pair position (NCBI build 36)	MAF	Discovery cohort ethnicity	Reference
ICBP-GWAS for PP and MAP						
rs13002573	FIGN	2	164,623,454	0.20	European	Wain et al., 2011
rs1446468	FIGN	2	164,671,732	0.47	European	
*rs319690	MAP4	3	47,902,488	0.49	European	
*rs871606	CHIC2	4	54,494,002	0.15	European	
*rs2071518	NOV	8	120,504,993	0.17	European	
*rs17477177	PIK3CG	7	106,199,094	0.28	European	
rs2782980	ADRB1	10	115,771,517	0.19	European	
*rs11222084	ADAMTS8	11	129,778,440	0.37	European	
Extreme case/control design						
*rs13333226	UMOD	16	20,273,155	0.17	European	Padmanabhan et al., 2010
Women's Genome Health Study						
*rs2898290	BLK-GATA4	8	11,471,318	0.47	European	Ho et al., 2011
Candidate genes – subset of GWAS						
*rs2004776	AGT	1	228,915,325	0.24	European	Johnson et al., 2011
*492	ADRB1	10	115,795,046	0.27	European	

This table lists all significantly associated SNPs with blood pressure per study. * indicates the study which reported the first association at this locus, the “40 independent blood pressure loci.” Some studies found associations at the same locus, but the index SNP reported differed. In some cases the reported SNP was in high LD, for others it was an independent signal at a locus. The “locus nickname” indicates the genes nearest to the associated genetic variant as described in the original papers. Chr = chromosome, bp = base pair, MAF = minor allele frequency.

Meta-analyses of GWAS to Discover Blood Pressure Genes

The first large-scale meta-analyses of GWAS results for SBP, DBP, and case/control hypertension were published in May 2009 by two large international consortia, Global BPgen (GBPG) and the Cohorts for Heart and Aging Research in Genome Epidemiology (CHARGE) (Levy et al., 2009; Newton-Cheh et al., 2009a). Both consortia analyzed approximately 2.5 million SNPs (directly genotyped and imputed) in large numbers of individuals of European ancestry (GBPG N=34,433 and CHARGE N=29,136), and both followed up their top 10 independent signals from each scan by performing a simultaneous reciprocal exchange of association results, with the GBPG consortium also following up 12 significant signals by direct genotyping in a further 71,225 individuals of European ancestry.

Each consortium identified genome-wide significant ($P < 5 \times 10^{-8}$) SNP associations at eight distinct loci. Of these, three loci were simultaneously discovered by both consortia, and one association identified by CHARGE was the same as the previously discovered association at the *ATP2B1* locus (Cho et

al., 2009); hence, in total, 12 novel associations were discovered (Table 44.1). The majority of the genome-wide significant SNPs were associated with both SBP and DBP and odds of hypertension, with the same direction of effect. The associated SNPs were common, with a minor allele frequency (MAF) >5%, and the effect sizes were ≤ 1.0 mmHg for SBP and ≤ 0.5 mmHg for DBP.

Since the GBPG and CHARGE meta-analyses, there has been a steady flow of new BP loci discoveries. Association at a SNP located near *CASZ1*, which had showed suggestive association in the CHARGE meta-analysis results, was replicated in samples of East Asian (Japanese) ancestry (Takeuchi et al., 2010). Combining the CHARGE meta-analysis results with data from a single, extremely large cohort of 23,019 individuals from the Women's Genome Health Study (WGHS) led to the discovery of an association near the *BLK-GATA4* genes (Ho et al., 2011). This association is located on chromosome 8 in a large polymorphic inversion, in a linkage disequilibrium (LD) block spanning many genes, and allelic imbalance has also been reported at this locus (Nusbaum et al., 2006; Wagner et al., 2010). The Asian Genetic Epidemiology Network Blood Pressure (AGEN-BP) GWAS study meta-analyzed GWAS results from 19,608 individuals of East

Asian ancestry, followed up top hits in a further 31,000 individuals also of East Asian ancestry, and discovered six significant associations with BP, near *ST7L/CAPZA1*, *FIGN/GRB14*, *ENPEP*, *NPR3*, *ALDH2*, and *TBX3* (Kato et al., 2011). The association at the *TBX3* locus was independent ($r^2 = 0.001$ in Utah residents with Northern and Western European ancestry (CEU)) to the variant previously reported by CHARGE (Levy et al., 2009).

Padmanabhan and colleagues performed an “extreme case/control” GWAS comparing highly selected hypertensive cases (top 2% of the population) versus controls selected for low BP and low occurrence of cardiovascular events (bottom 9% of the population) (Padmanabhan et al., 2010). Despite genotyping a discovery sample of fewer than 4000 individuals, the stringency of the ascertainment scheme meant that this study discovered a novel SNP at *UMOD*, which was validated by follow-up in a further 36,386 individuals. The SNP allele associated with higher risk of hypertension had previously been observed to be also associated with impaired renal function (as measured by estimated glomerular filtration rate) and higher risk for chronic kidney disease (Kottgen et al., 2009). Johnson and colleagues selected 30 genes that were known targets for anti-hypertensive drugs and tested SNPs in this “candidate gene” set for association with BP and hypertension, using the CHARGE meta-analysis results. With follow-up using GBPG meta-analysis and WGHS GWAS results, genome-wide significant associations at two loci, angiotensinogen (*AGT*) and the beta-adrenergic receptor 1 (*ADRB1*) were discovered (Johnson et al., 2011). The association at *AGT* was the same as the one previously reported by Watkins and colleagues in a smaller candidate gene study (Watkins et al., 2010).

Although there is wide variation in study designs (e.g., studies in populations with different ethnic ancestries, cases/controls ascertained from the extremes of the population BP distribution, or testing only “candidate gene” subsets of GWAS data), it is unclear whether the new discoveries are being made as a direct consequence of the different study designs, or are merely a reflection of the fact that all genetic association studies for BP have been somewhat underpowered. Hence, each study (regardless of design) would detect a more-or-less random subset of the likely hundreds of genetic associations with individually small effect sizes (Park et al., 2010). The latter hypothesis is supported by the observation that GBPG and CHARGE, two large studies with very similar overall designs, had relatively little overlap in the loci that reached discovery significance thresholds (Munroe et al., 2009).

Many of the genetic associations just described have subsequently been replicated in samples of different ancestry from where they were initially discovered, including in East Asian (Hong et al., 2010a, b; Kato et al., 2011; Liu et al., 2011; Niu et al., 2010; Takeuchi et al., 2010), South Asian (Newton-Cheh et al., 2009a), and African ancestries (Fox et al., 2011; Zhu et al., 2011).

International Consortium for Blood Pressure Genome-wide Association Studies

In the autumn of 2008, GBPG and CHARGE joined forces, and with additional GWAS studies formed a new BP genetics

consortium, the International Consortium for Blood Pressure Genome-wide Association Studies (ICBP-GWAS). This consortium evaluated associations between 2.5 million SNPs and SBP and DBP, and a second project focused on mean arterial pressure (MAP) and pulse pressure (PP). MAP and PP are calculated from SBP and DBP, but testing for association with MAP may increase power to detect genetic variants that influence both SBP and DBP with concordant effects, and testing for association with PP increases power to detect some genetic variants that influence SBP and DBP with discordant effects.

The meta-analysis of GWAS for SBP and DBP was performed in 69,395 individuals of European ancestry, and was followed by a three-staged validation study using 133,661 additional individuals of European ancestry (Ehret et al., 2011). A total of 29 SNPs at 28 loci were found to be significantly associated with SBP and DBP (all with $P < 5 \times 10^{-9}$), of which 16 of the associations were novel findings (Table 44.1), with one of the associations (at *NPR3*) discovered simultaneously by AGEN-BP (Kato et al., 2011). Analyses in this enlarged dataset did not support the association at the *PLCD3* locus that was reported previously by GBPG, illustrating that even large GWAS meta-analyses are susceptible to false positive results (which are controlled at 5% *per phenotype* per study by the conventional genome-wide significance threshold). The effect sizes of the new variants were similar to findings from other GWAS BP studies (mostly ≤ 1 mmHg for SBP and ≤ 0.5 mmHg for DBP), and observed directions of effect were concordant for SBP, DBP, and odds of hypertension.

A meta-analysis of GWAS for MAP and PP was performed in 74,064 individuals of European ancestry (Wain et al., 2011). Using “look-ups” in GWAS results from a further 48,607 individuals meant that a larger number of SNPs (99 in total) selected at a less stringent threshold ($P < 1 \times 10^{-5}$) could be followed up and potentially validated. This strategy revealed eight genome-wide significant associations; five for PP near *FIGN*, *CHIC2*, *PIK3CG*, *NOV*, and *ADAMTS8*, and three for MAP near *FIGN*, *ADRB1*, and *MAP4*. The SNPs near *FIGN* associated with PP and with MAP are two independent SNPs not in linkage disequilibrium (LD) in Europeans ($r^2 = 0.054$ in HapMap CEU), suggesting possible multiple causal variants. One of the SNPs near *FIGN* is the same as recently reported by Kato and colleagues (2011). The association at *ADRB1* is not in strong LD ($r^2 = 0.14$ in CEU) with the variant reported previously by Johnson and colleagues (2011).

Previous work had shown that some of the 13 significant associations discovered by GBPG and CHARGE in European ancestry samples also showed significant associations in samples of non-European ancestries (Hong et al., 2010a, b; Kato et al., 2011; Liu et al., 2011; Niu et al., 2010; Takeuchi et al., 2010; Zhu et al., 2011). To study this systematically in the largest sample sizes available, the ICBP-GWAS consortium tested the 29 SNPs for association with SBP and DBP in meta-analyses of results from non-European ancestries. Some of the individual SNPs showed significant associations in populations of East- or South Asian ancestry (or both) after

correction for multiple testing (Ehret et al., 2011). The general lack of statistically significant associations likely reflects a lack of power due to the fact that the available sample sizes were small compared to the discovery sample size in Europeans. Arguably, the most meaningful analysis of ancestry-specific effects (or lack of effects) is to test whether each SNP is associated with different effect sizes (on a mmHg-per-allele scale) in different ancestries, which is equivalent to testing for a genotype-by-ancestry interaction effect and allows for allele frequency differences between populations (because, for example, SNPs monomorphic in a given population have infinitely wide confidence limits on a mmHg-per-allele scale). Using effect size estimates for European ancestry samples that are free of winners' curse bias, there is no evidence of such ancestry-specific effects (Figure 44.1A and B). This analysis addresses the most biologically informative question, whether there is evidence that an allele would be associated with a different effect size if it was segregating in multiple populations. Hence, on the data currently available, although genotype frequencies do differ between populations of different ancestries, there is no evidence that the expected phenotype given a particular genotype depends on population ancestry (i.e., the biological mechanisms that determine phenotype as a function of genotype are the same for all populations). If this is true more generally (beyond the 29 SNPs studied here by ICBP-GWAS for SBP and DBP), future studies could increase power by combining data from populations of multiple ancestries in a single meta-analysis, as has been done for other phenotypes [Chambers et al., 2010; Coronary Artery Disease (CAD) Genetics Consortium, 2011].

NEW INSIGHTS INTO BLOOD PRESSURE BIOLOGY

To date, large-scale meta-analyses of GWAS and other approaches have revealed 40 genetic loci for BP and hypertension. The genetic variants discovered are all common (MAF > 5%), which is expected because such variants are better covered by GWAS genotyping arrays and because association tests are more powerful for common variants. Of the 29 associations with SBP and DBP reported by ICBP-GWAS, for example, many of the associated SNPs are intergenic, with the nearest gene located several kb (kilobasepairs) away, whereas eight are within genes and are potentially functional as encoding amino acid changes in the protein sequence (non-synonymous SNPs; nsSNPs). Functional mechanisms involving gene regulation are suggested for at least 5/29 SNPs, which are *cis*-acting expression SNPs (eSNPs) associated with the expressed transcript levels for nearby genes (Ehret et al., 2011). Of all the robustly associated BP loci (Table 44.1), many have at least one biologically plausible gene in the associated interval (e.g., *NPPA*, *NPPB*, *CYP17A1*, *GUCY1A3*, *GUC1B3*, *NPR3*, *ADM*, *GNAS*, *EDN3*, *ENPEP*, *GATA4*, *ADRB1*, and *AGT*).

Some of the recently reported genetic associations are in or near genes previously suspected to affect BP on the basis of prior functional and physiological experiments. However, despite *AGT* being a known component of the RAAS and one of the most intensively studied candidate genes, *ADRB1* being a known target for beta-blockers, and *ADM* encoding the adrenomedullin peptide with known vasodilatory properties, the small apparent effect sizes (for all genetic variants tested so far) have meant that very large sample sizes were needed to obtain robust confirmation of an association between BP and common genetic variation at these loci. The GWAS also identified genetic variants associated with BP that are in or near several genes that are part of the natriuretic peptide-guanylate cyclase-nitric oxide signaling pathway. Three distinct SNPs have now been reported near *NPPA* and *NPPB* (Newton-Cheh et al., 2009a, b; Tomaszewski et al., 2010), one SNP near the guanylate cyclase α and β subunits (*GUCY1A3-GUCY1B3*) (Ehret et al., 2011) and two SNPs near the C-type natriuretic peptide receptor (*NPR3*) (Ehret et al., 2011; Kato et al., 2011).

Many of the newly discovered BP loci do not contain genes that have previously been implicated in BP or cardiovascular disease. However, several of the genes have been studied in other contexts and have known functions that engender novel and potentially testable mechanistic hypotheses. One such example is the hemochromatosis (*HFE*) gene, where known mutations cause hereditary hemochromatosis, a disorder of iron overload that leads to hepatic cirrhosis and other complications (Pietrangelo, 2010). A second example is solute carrier family 39, member 8 (*SLC39A8*), which encodes a zinc transporter previously shown to play a role in cellular importation of zinc at the onset of inflammation. Its expression can be induced by tumor necrosis factor alpha (TNF- α) (Besecker et al., 2008), and this protein has also been implicated in cadmium and manganese transport (Himeno et al., 2009). The SNPs in these genes associated with BP are both nsSNPs: H63D in *HFE* is a low-penetrance allele for hereditary hemochromatosis, and A391T in *SLC39A8* has also been associated with high-density lipoprotein levels (Teslovich et al., 2010) and body mass index (Speliotes et al., 2010). Functional studies of these genes and their effects on BP and CVD, using, for example, transgenic knockout mouse model systems, will be an interesting area for future research.

DEVELOPING NEW THERAPIES FOR CARDIOVASCULAR DISEASE

Although each genetic variant exhibits only a modest effect on BP (mostly <1 mmHg for SBP and <0.5 mmHg DBP per risk allele), this does not necessarily correlate with efficacy of a therapeutic agent at the level of the gene product. In this context, the examples of HMG CoA reductase (*HMGCR*) and cholesterol esterase transfer protein (*CETP*) are widely cited. Genetic variants in or near these genes are associated with small effects on low-density lipoprotein (LDL) cholesterol and